Cytosorbents (CTSO) CEO Phillip Chan Buys $4.4K of Stock
Phillip Chan, CEO of CTSO, acquired 10,333 shares in a recent transaction.
Reviewed by automated data checks against the source filing. How we make and check alerts
Phillip Chan, Chief Executive Officer at Cytosorbents Corporation ($CTSO), bought 10,333 shares at an average price of $0.43, worth about $4,443.19, on June 15, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CTSO is down 4.4% after 1 week, down 9.9% after 1 month and down 52.4% to date (from the $8.64 close on Jun 15, 2026).
CTSO
Cytosorbents Corporation
Key Points
- Phillip Chan, CEO of CTSO, bought 10,333 shares at $0.43 each on June 15, 2026, totaling $4,443.19.
- Shares of CTSO traded around $0.40, with various institutional activities reported by peers like BlackRock and Vanguard.
- Analysts like D. Boral Capital maintain a 'buy' rating with a $10 target, while HC Wainwright rates it 'hold'.
Get $CTSO trade alerts by text
We text you when insiders, Congress or big funds trade $CTSO. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Cytosorbents Corporation alert may contain errors. Disclosures
Phillip Chan, the Chief Executive Officer of CTSO, recently increased his stake in the company by purchasing 10,333 shares. The transaction took place on June 15, 2026, at an average price of $0.43 per share, amounting to a total value of $4,443.19. This move was not part of a pre-planned trading arrangement.
Insider Buying and Selling at Cytosorbents Corporation
Phillip Chan has been actively buying shares of CTSO. On June 12, 2026, he acquired 251,136 shares at $0.40 each. Previously, on November 18, 2025, he purchased 200,000 shares at $0.64 each. Meanwhile, Peter Mariani, the Chief Financial Officer, sold 10,548 shares at $1.09 each on August 19, 2025.
Other Institutional Activity in CTSO
Among CTSO's institutional investors, Avenir Corp reduced its position by 14,323 shares, ending with 5,215,776 shares valued at approximately $2,953,694. Vanguard Capital Management LLC significantly increased its holdings, adding 1,879,989 shares to reach a total of 1,879,989 shares worth $1,064,074. Skylands Capital, LLC cut its stake by 147,017 shares, holding 1,707,498 shares valued at $966,956. Neuberger Berman Group LLC grew its position by 57,367 shares, totaling 1,683,007 shares worth about $950,776. BlackRock, Inc. also added 12,441 shares, bringing its total to 782,992 shares, valued at $443,408.
Cytosorbents Corporation Stock Down 93.0%
Shares of CTSO traded around $0.40. The stock has experienced various institutional activities and insider transactions, reflecting ongoing interest and adjustments by stakeholders.
Analysts Set New Price Targets
On January 12, 2026, D. Boral Capital maintained its 'buy' rating for CTSO, setting a price target of $10. HC Wainwright & Co. maintained a 'hold' rating with a $0.75 target on November 14, 2025. The consensus among analysts reflects a mixed outlook, with a recommendation key leaning towards 'hold' and a mean target price indicating moderate expectations.
About CTSO
CTSO is a company involved in the medical technology sector, focusing on developing and commercializing innovative therapies to treat life-threatening conditions. The company is headquartered in the United States and is led by CEO Phillip Chan.
Bottom Line
Phillip Chan's recent purchase of CTSO shares highlights his ongoing commitment to the company. While insider buying can signal confidence in the company's prospects, it's important to remember that these transactions are not always indicative of future performance. Investors and analysts continue to monitor CTSO's developments closely.
Related Filing Alerts
Source: Phillip Chan's Form 4 filing on $CTSO (Jun 15, 2026). Find the original filing: CTSO Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts